AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open-Label Extension on Safety, Biomarkers, and Disease Progression.

Jean-Christophe Corvol, Marie Lebouteux, Cecilia Estrella(CHemProtect (Czechia)), Mickaël Alexandre Obadia(Fondation Ophtalmologique Adolphe de Rothschild), Luc Defebvre(Hôpital Roger Salengro), Graziella Mangone(Sorbonne Université), Aurélien Blondel(CHemProtect (Czechia)), Louise‐Laure Mariani(Centre National de la Recherche Scientifique), Artin Karapet(CHemProtect (Czechia)), Philippe Verwaerde(CHemProtect (Czechia)), Noelle Callizot, Nicolas Carrière, Sara Sambin, Günter Höglinger, Caroline Moreau, Jean-Philippe Brandel, David Devos, Olivier Defert(CHemProtect (Czechia))

DZNE Pub

January 1, 2025

Cited by 0

Related Papers

Trial of Lixisenatide in Early Parkinson’s Disease

|New England Journal of Medicine|2024|302

Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts

|The Lancet Neurology|2017|189

Penetrance estimate of <i>LRRK2</i> p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry

|Movement Disorders|2017|170

Neurologic manifestations associated with COVID-19: a multicentre registry

|Clinical Microbiology and Infection|2020|142

Cerebral venous thrombosis associated with COVID-19 infection: Causality or coincidence?

|Journal of Neuroradiology|2020|95